{"id":"NCT00405756","sponsor":"Celgene Corporation","briefTitle":"A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.","officialTitle":"A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (Revlimid®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In Subjects With Newly Diagnosed Multiple Myeloma Who Are 65 Years Of Age Or Older","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2009-11","completion":"2016-04","firstPosted":"2006-11-30","resultsPosted":"2012-05-11","lastUpdate":"2017-01-11"},"enrollment":459,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Newly Diagnosed Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Lenalidomide: Double-blind Induction","otherNames":["Revlimid"]},{"type":"DRUG","name":"Melphalan","otherNames":["Alkeran"]},{"type":"DRUG","name":"Prednisone","otherNames":[]},{"type":"DRUG","name":"Aspirin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Lenalidomide: Double-blind Maintenance","otherNames":["Revlimid"]},{"type":"DRUG","name":"Lenalidomide: Open-label","otherNames":["Revlimid"]}],"arms":[{"label":"MPR+R","type":"EXPERIMENTAL"},{"label":"MPR+p","type":"EXPERIMENTAL"},{"label":"MPp+p","type":"OTHER"}],"summary":"The purpose of this study is to determine whether lenalidomide is safe and effective in the treatment of patients with newly diagnosed Multiple Myeloma who are 65 years of age or older.","primaryOutcome":{"measure":"Kaplan Meier Estimates of Progression-free Survival (PFS) Based on the Response Assessment by the Central Adjudication Committee (CAC)","timeFrame":"up to 165 weeks","effectByArm":[{"arm":"MPR+R","deltaMin":136.1,"sd":null},{"arm":"MPR+p","deltaMin":62.1,"sd":null},{"arm":"MPp+p","deltaMin":56.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG001 vs OG002","p":"0.134"}]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":98,"countries":["Australia","Austria","Belarus","Belgium","Czechia","Denmark","France","Georgia","Germany","Greece","Ireland","Israel","Italy","Netherlands","Poland","Russia","Spain","Sweden","Switzerland","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["23242595","22571200","25840600"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":66,"n":150},"commonTop":["Neutropenia","Anaemia","Thrombocytopenia","Leukopenia","Fatigue"]}}